There were only one to four eligible studies done on Autoimmune diseases cause significant and chronic 11 other diseases, and no prevalence studies on 6 dismorbidity and disability. The actual number of per-eases. Incidence studies were less frequent but the sons in the United States that are affected by autoim-largest number of studies were conducted on IDDM (n mune diseases and the resultant magnitude of their Å 37) and MS (n Å 28), followed by Graves' disease/ impact on the public's health are limited to a few spe-hyperthyroidism, glomerulonephritis, primary biliary cific diseases. In order to understand the clinical, pub-cirrhosis, rheumatic fever, rheumatoid arthritis, sclelic health and economic importance of these diseases roderma, and SLE ( §9). On the other 11 diseases, there it is necessary to have estimates of incidence and prev-were one to six eligible studies, and no studies on 5 alence rates in the population. In this analysis, we esti-diseases. There were no eligible incidence or prevamate the number of persons affected by 24 autoim-lence studies on Goodpasture's syndrome, idiopathic mune diseases in the United States by applying mean thrombocytopenia purpura, or relapsing polychonweighted prevalence and incidence rates obtained dritis. Overall we estimate that 8,511,845 persons in from published articles to U.S. Census data. The study the United States or approximately 1 in 31 Americans was restricted to 24 autoimmune predefined diseases are currently afflicted with one of these autoimmune for which there was direct or indirect evidence for diseases. The diseases with the highest prevalence autoimmune pathogenesis. Subsequently, we used rates were Graves'/hyperthyroidism, IDDM, pernicomputerized search software and ancestry searching cious anemia, rheumatoid arthritis, thyroiditis, and (bibliographies) to conduct a comprehensive search of vitiligo, comprising an estimated 7,939,280 people or articles published from 1965 to the present. Eligible 93% of the total number estimated. Glomerulonephristudies included those which adhered to standard dis-tis, MS, and SLE added an estimated 323,232 people. ease definitions and which included population-based The prevalence of the other diseases reviewed were estimates of incidence or prevalence rates. Mean rare, less than 5.14/100,000. Most diseases were more weighted incidence and prevalence rates were calcu-common in women. From the incidence data we estilated from eligible published studies with greater mate that 237,203 Americans will develop an autoimweight proportionately given to larger studies. The mune disease in 1996 and that approximately 1,186,015 mean rates were then applied to the U.S. Census popu-new cases of these autoimmune diseases occur in the lation figures to estimate the number of persons cur-United States every 5 years. Women were at 2.7 times rently afflicted with each disease and the number of greater risk than men to acquire an autoimmune disnew cases occurring each year in the United States. ease. After reviewing the medical literature for inciOnly U.S. and European studies were used to estimate dence and prevalence rates of 24 autoimmune disprevalence and incidence rates when there were at eases, we conclude that many autoimmune diseases least six eligible studies available for a disease. When are infrequently studied by epidemiologists. As a rethere were fewer than six studies, all available studies sult the total burden of disease may be an underestiwere included, regardless of country of origin. The mate. The number of studies performed on a disease number of eligible incidence and prevalence studies has not necessarily been related to the public health found in the literature varied considerably between burden of the conditions reviewed. Individual autoimthe 24 autoimmune diseases selected. The largest num-mune diseases have often been studied as separate ber of eligible prevalence studies were conducted on entities; however, many share common mechanisms of multiple sclerosis (MS), rheumatoid arthritis, and sys-induction and pathogenesis. Thus, considered as a temic lupus erythematosus (SLE) ( §23), followed by group of disorders autoimmune diseases are an iminsulin-dependent diabetes (IDDM), myasthenia gra-portant cause of morbidity and affect a large number of Americans. Further epidemiologic research is urvis, primary biliary cirrhosis, and scleroderma ( §7).
INTRODUCTION
cally determined model. Using this list we conducted a comprehensive search of the medical literature since 1965. Data from studies fulfilling our disease definition Autoimmune diseases are often associated with severe and chronic morbidity (e.g., rheumatoid arthritis, and study design criteria were used to compute weighted mean incidence and prevalence rates on each systemic lupus erythematosus, and rheumatic fever) as well as being an important cause of mortality (e.g., disease. We applied these rates to the 1996 population projections from the U.S. Census Bureau (5, 6) to estiscleroderma and myocarditis). Since many diseases occur among young and middle-aged adults, they also are mate the number of persons currently affected with an autoimmune disease and the number who will develop significant contributors to productive years lost in this part of the population. Population-based epidemiologic an autoimmune disease in 1996. research on autoimmune diseases has focused on multiple sclerosis, rheumatoid arthritis, and insulin-depen-METHODS dent diabetes, while most other autoimmune diseases appear to have received little or no attention from epi-Criteria for an Autoimmune Disease demiologists on a population level. In particular, the prevalence and incidence of autoimmune diseases reTwenty-four autoimmune diseases were selected for study. Twenty-one were selected using the criteria of mains poorly understood, and their collective importance as a public health problem remains largely un-Rose and Bona (4), which define an autoimmune disease according to the existence of direct proof or indiknown. For some of the most common diseases, prevalence and incidence rates are readily available (1, 2). rect evidence of autoimmune pathogenesis. Direct proof of autoimmune etiology was defined by disease reproHowever, most of the epidemiologic data available on apparently less common diseases have been obtained ducibility through direct transfer of autoantibody or autoantigen-specific T cells to animals or into in vitro from hospital-or clinic-based case series studies. Valid incidence and prevalence rates cannot be estimated systems. Indirect evidence of autoimmune etiology was defined by disease reproducibility in animals through from these case series unless all cases are identified within a defined period of time and the population at experimental immunization with the implicated autoantigen or through cell transfer from animals with risk can be accurately enumerated. As a result, there is an urgent need to estimate the number of individuals genetically determined models of disease. Further, Rose and Bona accepted indirect proof of autoimmunity currently with at least one autoimmune disease in the United States (e.g., prevalent cases) and the number under conditions where autoantibodies have been isolated or self-reactive T cells can be identified from the of new cases (incident) per year to determine both the public health impact of these disorders and the signifi-major target tissues of those affected with the disease (4). While azoospermia was included on the list of Rose cant gaps in our knowledge of the epidemiology of these conditions. and Bona, we did not include it because studies designed to detect the prevalence of anti-sperm or antiAutoimmune diseases have usually been studied as separate entities, each disease individually, rather testicular antibodies (which defines azoospermia) in the general population have not been performed. Furthan as a group of disorders. From a public health, biologic, and health services standpoint, it is important thermore, detection of cases of azoospermia is most likely to occur in an infertility clinic, which would be to consider the prevalence and incidence of these disorders as a group. There is evidence that these diseases unrepresentative of all cases of azoospermia. Because of their importance and the availability of data, we cluster so that multiple cases appear in one family; sometimes more than one autoimmune disease occurs added three diseases to the list of Rose and Bona: chronic active hepatitis, glomerulonephritis, and rheuin the same patient. Moreover, mechanisms of induction and pathogenesis and methods of treatment may matic fever. Addition of these diseases is based on strong circumstantial evidence of an autoimmune etiolbe shared by many autoimmune diseases (3), such as in cancer.
ogy together with acceptable epidemiological studies. We have not included Reiter's syndrome because the Since the autoimmune etiology of many disorders is in dispute or poorly characterized, we decided to focus pathology may be due to a direct effect of infection at the site of the disease rather than an autoimmune proon a group of disorders which are generally agreed to cess following infection (7). Studies conducted solely erythematosus (SLE). Within some of these standardized criteria there are gradations of certainty for disamong children who have Graves' disease/hyperthyroidism, thyroiditis/hypothyroidism, or myocarditis ease diagnosis. For example, rheumatoid arthritis may be classified as definite, probable, or possible based on were mentioned separately from those conducted among adults. The number of children affected by a the number of clinical characteristics that satisfy the American Rheumatological Association diagnostic criparticular disease was added to the total population burden in addition when the adult rate was based on teria. On the diseases where this applies, the level of certainty accepted is specified in Table 1 . Otherwise, ages greater than the childhood age group (e.g., thyroiditis/hypothyroidism).
the diagnosis was assumed to be definite. The majority of diseases included in our analysis do Disease Definitions not have well-standardized published criteria. We have selected criteria for each disease which utilize clinical The specific disease definitions which were utilized judgment and appropriate laboratory analyses that to select articles for inclusion into this analysis are best define each disease. listed in Table 1 (8-311 ). For epidemiologic purposes it is, of course, ideal to have standardized disease defi-Literature Search nitions in order to compare incidence and prevalence rates across different studies and populations. Where Medline was thoroughly searched for articles between 1965 and 1995 in order to obtain all articles standardized definitions existed and were widely used, these criteria were utilized as inclusion criteria for the for infrequently studied diseases. All articles within a disease with a key word or subject of epidemiology, following diseases: multiple sclerosis, rheumatic fever, rheumatoid arthritis, scleroderma, and systemic lupus prevalence, incidence, disease susceptibility, or risk factors were reviewed. This combination of words ap-were pooled to maintain the maximum concurrence in socioeconomic status and ethnicity. When there were peared to maximize selection of articles. Articles cited in the bibliography of the articles reviewed were also fewer than six eligible studies, all available studies, including those from regions other than North America evaluated for inclusion (ancestry searching). Citations from the book entitled ''Epidemiology of Rheumatic and Europe, were also included in order to calculate the pooled rates. Studies from ''other'' countries were Disease'' (2) were largely included. Every attempt was made for this list of articles to be inclusive. In some included so that within the limitations of the available studies, all estimates of disease rates remained based cases an article or book was not accessible. Articles in languages other than English were selected when they on the largest possible pool of data. The diseases on which the pooled prevalence rate was not solely based were cited in a bibliography and when they were available in a U.S. library. on U.S./Canadian or European studies were polymyositis, Sjogren's, thyroiditis/hypothyroidism, uveitis, A thorough search of the literature was performed for rheumatic fever and rheumatic heart disease. Al-and vitiligo. For pooled incidence rates, the diseases which were not solely based on U.S./Canadian or Euromost all of the studies on rheumatic heart disease were done in developing countries, and many of the studies pean studies were streptococcal glomerulonephritis, myocarditis, myocarditis children, and pemphigus. on rheumatic fever from the United States were performed in populations that were not representative of
The incidence or prevalence rate from each study within a disease category contributed proportionately the U.S. population. Thus, a rate from the Centers for Disease Control 1994 was utilized for rheumatic fever to the mean incidence or prevalence rate based on the population size of that study. The proportion or weight (312) . Rheumatic heart disease rates were not estimated because the rates would be derived from studies was determined by dividing the study population denominator by the total of all the study population dethat are not relevant to the epidemiology of the disease in the United States.
nominators for each disease. Only studies with a population denominator available were included in the calInclusion/Exclusion Criteria culation. This weighted method was used on the assumption that larger studies have more precise estiMost studies that were reviewed and evaluated were mates of rates than smaller studies. Most autoimmune selected for inclusion into our analysis. Articles were diseases are more prevalent among women. Thus, we excluded when there was no incidence or prevalence estimated the ratio of males to females affected by usrate given (e.g., a case series without a population de-ing a weighted average of the ratios reported in the nominator) or where rates could not be calculated from studies, where the weights were again proportional to the data available in the article. In order to maintain the prevalence denominator population. The ratios reconsistency, however, studies which did not explicitly ported were from prevalent or incident cases depending meet the criteria defined in Table 1 were excluded, as upon which was reported in each article. were studies which did not clearly state their disease
The total population affected by each of the 24 autodefinition. Papers were also excluded when the authors immune diseases was estimated using the May 1996 did not clearly differentiate between definite, probable, population projection by the U.S. Census Bureau (5, or possible cases of disease, as in the case multiple 6). Different age categories from the Census were apsclerosis and rheumatoid arthritis. In general, inclu-plied to different diseases. The age category most fresion criteria were designed to be conservative such that quently cited across studies was utilized. For example, any bias inadvertently introduced into prevalence and insulin-dependent diabetes (IDDM) is mostly studied incidence estimates would lead to underestimation of in people less than 20 years old, with some variation disease rates.
in the individuals included in the denominator. To estiIn addition, when prevalence or incidence rates were mate the number of persons currently afflicted with stratified by demographic subgroup but no overall rate IDDM, the average prevalence rate was multiplied by was given, the lowest rate quoted was used. The most the number of persons less than 20 years old in May recent incidence or prevalence was quoted when rates 1996. To arrive at the number of men and women afwere presented consecutively over several years of fol-fected, the average percentage of men and women aflow-up and no summary rate was given.
flicted computed above was multiplied by the total number of persons currently afflicted by the disease.
Technique for Estimating Pooled (Weighted Mean)
When estimates for individual autoimmune diseases Rates were calculated, differences in trends over time, by ethnic group, and by latitude were not always available or Weighted mean incidence and prevalence rates were calculated for each disease. When there were at least were poorly documented. In some populations, specific ethnic groups (e.g., American Indians) may have a gesix eligible studies on a specific autoimmune disease, only rates from the United States, Canada, and Europe netic susceptibility that confers higher rates than in the general U.S. population. However, studies performed exclusively on minority ethnic groups were usuNumber of Population-Based Prevalence Studies for 24 ally small and contributed less weight to the overall The number of population-based prevalence (Table Primary biliary 2) and incidence (Table 3) listed in Table 1 .
Thyroiditis/hypothyroidism All ages 1 0 0
Number of Prevalence Studies
The highest number of prevalence studies (Table 2) Vitiligo 1 0 2 conducted throughout the world were for multiple sclerosis (MS) (n Å 80), rheumatoid arthritis (n Å 38), and a Criteria (Table 1) : studies with a male, female, and/or population prevalence rate. SLE (n Å 23). There were 49 eligible studies from Europe on MS, 16 studies on MS from the United States/ Canada, and 15 from ''other'' countries ( Table 2 ). The United States/Canada and Europe each conducted 11 Among the 24 diseases examined, only 8 had at least eligible studies on rheumatoid arthritis, while 16 stud-seven eligible prevalence studies done. There were no ies were done in ''other'' regions. SLE was studied with eligible prevalence papers on Goodpasture's syndrome, almost equal frequency in all three regions. idiopathic thrombocytopenia purpura, or relapsing A moderate number of eligible prevalence studies polychondritis, nor autoimmune hemolytic anemia, were performed on insulin-dependent diabetes (n Å myocarditis, or pemphigus. For the other 11 diseases, 15), myasthenia gravis (n Å 9), primary biliary cirrho-between one and four prevalence studies were found sis (n Å 7), and scleroderma (n Å 9). Seven of the preva-in the literature on each disease. lence studies identified were conducted in Europe and eight in ''other'' regions on IDDM, while none were ini-Number of Incidence Studies tiated in the United States/Canada. All of the prevalence studies on myasthenia gravis and primary biliary The highest number of eligible incidence studies (Table 3) were carried out on IDDM (n Å 37) and MS (n cirrhosis were conducted in Europe with the exception of one study on myasthenia gravis from ''other'' areas. Å 28), the vast majority of which were from Europe for both diseases, 21 and 20, respectively (Table 3) . The An equal number of prevalence studies were done in the United States/Canada and Europe on scleroderma remaining incidence studies of MS and IDDM were about equally divided between the United States/Can-(n Å 4), while only one was done in ''other'' regions. incidence data were also available from several other countries. We found no studies with appropriate popuNumber of Population-Based Incidence Studies for 24 lation-based incidence data on Goodpasture's, ITP, or Nonetheless, the rates for other conditions are relatively conservative, and conditions for which there are a Criteria (Table 1) : studies with a male, female, and/or population no data were excluded and did not contribute to the incidence rate.
final estimate. Based on these data, we estimated 6,722,573 women and 1,789,273 men with autoimmune diseases in the United States. Overall 8,511,845 or 1 ada and the ''other'' regions. Graves' disease/hyperthy-in 31 Americans would be currently affected by an autoroidism (n Å 11), glomerulonephritis (n Å 13), rheu-immune disease. This number does not take into acmatic fever (n Å 17), rheumatoid arthritis (n Å 13), count the comorbidity of autoimmune diseases which scleroderma (n Å 10), and SLE (n Å 18) were the next would lower the total number affected by at least one most frequently studied autoimmune disorders that of these autoimmune diseases. provided population-based incidence rates. Glomerulonephritis, Graves' disease/hyperthyroidism, and pri-Incidence of Autoimmune Diseases mary biliary cirrhosis were more frequently studied in Europe than the United States. Two studies on Graves'
Based on eligible studies with population-based estimates of autoimmune disease incidence, we estimated disease/hyperthyroidism were done in both the United States/Canada and ''other'', and four studies on post-that in 1996 approximately 237,203 Americans will develop an autoimmune disease (Table 5) . Women would streptococcal glomerulonephritis were done outside of North America and Europe. Although more studies on be at greater risk, in that there will be 2.7 times more women (172,695) than men (64,506) who will develop rheumatic fever, rheumatoid arthritis, scleroderma, and SLE were initiated in the United States/Canada, an autoimmune disease. The diseases with the highest incidence rates from reviewed studies are rheumatoid Based on these data, we estimate that every 5 years 1,186,015 new cases of autoimmune disease occur in arthritis (23.7/100,000), thyroiditis/hypothyroidism (21.8/100,000), and uveitis (18.9/100,000), followed by the United States, assuming incidence rates remain constant. Graves' disease/hyperthyroidism (13.9/100,000) and IDDM (12.2/100,000). These diseases together represent 185,412 people or 78% of the total number of peo-Trends over Time ple estimated to develop disease in 1996. Using this same approach, we estimate that approximately 42, 137 For the six autoimmune diseases which had the largest number of prevalence estimates available (MS, new cases of primary glomerulonephritis (3.6/100,000), multiple sclerosis (3.2/100,000), polymyositis/dermato-myasthenia gravis, primary biliary cirrhosis, rheumatoid arthritis, scleroderma, and SLE), we investigated myositis (1.8/100,000), and SLE (7.3/100,000) would occur in 1996. Among the other six diseases reviewed the trend of prevalence values over time. Figure 1 displays the prevalence for each study plotted against the where an incidence study had been performed, the rates were all less than 1.0/100,000, affecting 7,159 year of publication, which was chosen because of the difficulty in precisely defining the prevalence period for people. In addition, the number of people with myocarditis, which was found at autopsy, would contribute each study. The points indicate those studies based on less than 100,000 individuals (/), 100,000 to 1,000,000 2,495 additional people. This number was determined from the rate times the number of deaths in 1993. (᭺), and more than 1,000,000 individuals (l). The dashed lines indicated the weighted average prevalence is lower than that in several of the prevalence studies shown. This is because the study with the lowest rate estimates, and the solid line indicates a least-squares regression line calculated with points weighted by the had the highest population number, which added more weight to the mean estimate. study population size. The trends over time were virtually flat for rheumatoid arthritis and SLE and increas-DISCUSSION ing in various magnitudes for the other four diseases, with the most evident increases in MS and primary biliWe have conducted a database and bibliography search for articles on the incidence and prevalence ary cirrhosis. The weighted mean rate for scleroderma FIG. 1. Prevalence rates of six autoimmune diseases by year of publication. The population size is indicated by the symbols: /, õ100,000; ᭺, 100,000-1,000,000; l, ú1,000,000. The prevalence rates are per 100,000 for all diseases.
rates of 24 autoimmune diseases. The greatest number logic studies for idiopathic thrombocytopenia purpura, Goodpasture's syndrome, or autoimmune hemolytic of prevalence studies which fit into our disease criteria were conducted on three well-known autoimmune dis-anemia.
In summary, the majority of autoimmune diseases eases, multiple sclerosis, rheumatoid arthritis, and systemic lupus erythematosus. The greatest number of we reviewed were significantly understudied. This is in view of the fact that an estimated 8,511,845 people eligible incidence studies were conducted on IDDM and multiple sclerosis. Although these diseases have re-are currently diagnosed with an autoimmune disease in the United States, an estimate which was derived ceived the most attention from epidemiologists, only rheumatoid arthritis is among the five autoimmune from the eligible published studies which met our criteria using weighted mean prevalence rates. Given that diseases which contribute the highest number of new cases per year. Approximately 176,049 new cases of the population of the United States is 264,755,000, this figure translates into one in 31 Americans who are afautoimmune disease per year are due to rheumatoid arthritis, thyroiditis/hypothyroidism, uveitis, and fected. The yearly incidence rate is also significant in that an estimated 237,203 Americans will develop an Graves' disease/hyperthyroidism. Rheumatoid arthritis is also among the four most prevalent autoimmune autoimmune disease in 1996. Because most autoimmune diseases are chronic diseases of long duration, it diseases, including Graves' disease/hyperthyroidism, rheumatoid arthritis, thyroiditis/hypothyroidism, and is not surprising that the number of persons currently affected is almost 36 times the number of persons that vitiligo; together they currently affect an estimated 7,539,825 people in the United States.
will develop an autoimmune disease each year. It was not possible to correct for age due to the absence of Several diseases with high incidence and/or prevalence rates are very infrequently studied in proportion age-specific prevalence rates in the literature. While geographical variations do exist for some autoimmune to the amount of disease attributed to them. Despite the strikingly high incidence and prevalence rates of diseases, such as multiple sclerosis, this was not the focus of this paper. both Graves' disease/hyperthyroidism and thyroiditis/ hypothyroidism we only found 3 and 4 eligible preva-
The estimated trends in prevalence rates over time showed some indication of increasing over time. Howlence studies, respectively, conducted on each of these diseases. Incidence studies of Graves' disease/hyper-ever, inference that this is due to a true increasing prevalence should be done only after other causes for thyroidism were conducted primarily among Europeans, in 7 of 11 eligible studies, while there were only an increase have been eliminated. For example, increases may be explained by better diagnosis or re-3 incidence studies on thyroiditis/hypothyroidism. Several other diseases with moderate or high prevalence porting, by improved study design, and/or because populations at higher risk are studied. rates (pernicious anemia and vitiligo) or high incidence rates (uveitis) were infrequently studied on a populaAutoimmune diseases are a challenge to study on a population level due to several factors. These include tion basis. The number of incidence or prevalence studies ranged from 0 to 4 for each disease. For example, the fact that many conditions are rare or at least uncommon, and that it is difficult to define and ascertain the estimated prevalence and incidence rates for glomerulonephritis are close to those for multiple sclero-cases. A large number of the diseases we reviewed are rare. Among the 18 diseases with at least one eligible sis, each contributing approximately 9500 and 8500 new cases per year, respectively. Nonetheless, there prevalence study, 11 had prevalence rates of less than 100 per 100,000 population and 7 had prevalence rates were approximately 40 times as many eligible prevalence studies and 2 times as many incidence studies of less than 6 per 100,000. This poses specific problems for epidemiologic data collection. Researchers must conducted on multiple sclerosis as on glomerulonephritis. In contrast, while the prevalence rates are rela-identify a very large population base in order to find enough cases to achieve valid estimates of prevalence. tively low for myasthenia gravis, primary biliary cirrhosis, and scleroderma (1.9-5.1/100,000), a moderate The ease by which cases will be found may depend on whether the disease requires hospitalization at some number of prevalence studies were conducted on each of these diseases, ranging between 7 and 9. In addition point. It is easier to identify hospital admissions for rare diseases than it is to locate cases of rare diseases to the diseases mentioned previously, there were a moderately large number of incidence studies on sclero-through private physicians' records or at health clinics in the absence of an active surveillance system and/or derma (n Å 10), SLE (n Å 18) and rheumatoid arthritis (n Å 13). Among the remaining diseases reviewed with mandatory disease reporting. Finding an adequate and accurate enumeration of cases requires collaboration low incidence and prevalence rates, Addison's disease of the adrenal, chronic active hepatitis, myocarditis, within the community. Obtaining records from physicians and clinics in a very large population is time pemphigus, and polymyositis/dermatomyositis were infrequently the focus of incidence or prevalence studies. consuming and may not result in high rates of compliance. This is also true for more prevalent diseases. In Finally, we were unable to locate any eligible epidemio-addition to case ascertainment, it is also crucial to iden-ducted in Europe as in the United States/Canada or in ''other'' regions. tify the population base from which the hospital cases or the private physician/clinic cases arose. In some inIn our attempt to estimate the mean incidence and prevalence rates for 24 diseases, we selected diseases stances, researchers conducted cases series studies whereby they identified all of the cases within a clinic, which are broadly accepted as having an autoimmune origin, and then included papers which fit a strict set but they did not enumerate the population from which these cases arose, nor the period of time during which of disease criteria. Our estimates might be conservative for a number of reasons. First, we have only selected they were collected. These studies could potentially have been important sources of prevalence or incidence diseases which are commonly considered to be autoimmune, based on laboratory evidence (4). Other redata had there been an appropriate denominator population enumerated. Case ascertainment is a formidable searchers may add to this list of diseases based on different criteria. This would lead to a greater overall constraint to studying rare and less prevalent autoimmune diseases, and it may be one explanation for the estimate of the number of persons affected by an autoimmune disease, compared to our estimate. Second, limited amount of data on the majority of these diseases.
current rates for some diseases might be higher than the mean rates we have estimated if there is an increasAnother constraint to doing research on autoimmune diseases is the lack of standardized definitions on most ing trend over time in disease rates. We computed mean rates from data collected over a maximum of 30 of the diseases we reviewed. With standardized criteria developed through consensus panels, researchers can years. Current rates might be higher due to implementation of improved diagnostic tools over time, allowing be more certain that they are accurately identifying cases, and that the cases are correctly categorized ac-for improved detection of cases. If there is an increase in rates over time due to improved diagnostic capabilicording to the level of certainty of the diagnosis. Some studies were excluded from our analysis because the ties, these mean rates would tend to be an underestimate of current rates, and, thus, an underestimate of authors did not state the criteria they used to define a case, or they did not indicate the certainty of diagnosis the number of people affected today. Additionally, if most of the rates that went into the calculation of the for diseases such as rheumatoid arthritis or multiple sclerosis where the level of certainty is included in the mean rate were from studies done in countries without improved diagnostic tools, the mean rates might be unstandardized criteria. Standardized definitions also allow researchers to compare incidence and prevalence derestimates of current U.S. rates as well. Thyroiditis may be an underestimate if one chooses to use histologrates across studies, knowing that the differences in rates are unlikely to be due to a difference in disease ical evidence of lymphoid cell infiltrates in the thyroid as the ''gold standard'' rather than biochemical or imcriteria. There is clearly a need for more consensus panels to be formed to address these issues. munological evidence (31). IDDM might also be an underestimate if some persons with Type 1 diabetes have Many autoimmune diseases are difficult to diagnose because autoantibodies, for example, are often found been classified with Type 2 diabetes.
Although we believe our weighted mean rates for the in normal, healthy individuals. This is the case for thyroiditis and SLE. Under these circumstances, cases vast majority of conditions and for the overall population burden were conservative, there were four inmay be overdiagnosed or undiagnosed due to lack of a clear ''cut point'' in serological tests. stances where our estimates of disease rates might be overestimates of current actual rates. The incidence of Bearing in mind the constraints mentioned that make epidemiologic research on autoimmune diseases rheumatic fever declined in this country until the 1980s when it began to reappear (219). It began to decline a challenge, we discovered that many autoimmune diseases are understudied and that many of the studies presumably through the use of antibiotic treatment for Group A streptococcal infection, improved hygiene, and we reviewed were incomplete from an epidemiologic perspective. Frequently, the number of cases, the popu-decreased crowding. Speculation about its reappearance leads to theories of renewed crowding, less comlation number, and/or the disease criteria were missing from papers, making it difficult to estimate mean popu-pulsive treatment of streptococcal infections, and reemergence of rheumatogenic strains. Most of the recent lation weighted incidence or prevalence rates. For some diseases there were no incidence or no prevalence rates. studies in the United States were conducted in Hawaii.
The ethnic mix of the Hawaiian population is different As a result, when the overall burden of disease was calculated some diseases had to be excluded from the to the mainland United States and it is likely these estimates may slightly overestimate rheumatic fever calculation, giving an underestimate of the true total burden. In addition, the actual burden of disease on the incidence in the rest of the United States. The rates ranged from 0.2 to 61 per 100,000 from 1973 to 1992. U.S. population must be estimated using rates derived outside North America, which in some cases might not Thus, we decided to use the reported disease rates in 1993 from the Centers for Disease Control to estimate be directly applicable. Twice as many studies were con-the current rate. In addition, the rates for poststrepto-pital records would be necessary to confirm disease diagnoses. If a sample is to include a large geographic coccal glomerulonephritis might be overestimates because four of five of the studies were from countries area, cooperation between health care providers in the region is crucial to obtain all cases, including hospital outside the United States. However, the rates for streptococcal glomerulonephritis alone were not used to esti-cases and community cases. This can be accomplished through intensive surveys of health care facilities and mate the total burden of disease. The rates for primary glomerulonephritis as a whole were. These studies patient advocacy groups, for example. Comorbidity of disease must be included in these surveys. With these were primarily from Europe. Seven of eight studies on rheumatic heart disease are from outside the United types of comprehensive efforts, we can get a better understanding of the true rates of disease in the United States and the other is among American Indians. These rates are extremely high, are not likely to be indicative States and in other regions of the world.
As a result of this analysis we found that autoimof U.S. rates, and were not included. No substitute rate was given. Finally, there were only two eligible studies mune diseases as a group are a significant source of morbidity in the world. Our estimate of over 8,500,000 on Sjogren's syndrome, one from China and one from Japan. The prevalence rate is high in the Chinese people with disease in the United States is certainly an underestimate because we restricted our analysis study, 774/100,000, and much lower in Japan, 13.9/ 100,000. Our estimates of the total burden of autoim-to well-characterized disorders for which there is substantial evidence of an autoimmune etiology and wellmune disease in the United States may also be high because it is not clear how many persons with one auto-documented epidemiological data. Autoimmune diseases represent a population burden and public health immune disorder will develop other disorders. Several studies have shown that 5-8% of persons with insulin-problem of considerable importance. Because many of these diseases are chronic and require intensive medidependent diabetes have clinical hypo/hyperthyroidism (313). Due to a lack of data on the rate of comorbidity, cal intervention, their impact on health service delivery appears to be underestimated. Although the actual imthe number of persons in the population affected by one or more conditions is difficult to estimate accurately. pact on costs and health service needs are unknown, it is clear that autoimmune diseases as a group have an Adding rates from each disease separately may overestimate the overall prevalence rate of persons with at impact on many aspects of modern life, including years of productive life lost, a decrease in quality of life, and least one autoimmune disease. With these caveats in mind, to our knowledge, we have compiled the most economic hardship. The time may have come to start to implicitly consider autoimmune diseases as a group comprehensive collection of and analysis of incidence and prevalence rates to date. Our estimates of the num-of related disorders rather than as a single independent entity. By considering these diseases as a group, not ber of persons affected by an autoimmune disease in the U.S. population is the most data-driven estimate only will it help to facilitate research efforts but it may improve diagnosis and health services to those in need. currently available and did not include contributions from conditions where no eligible data were available.
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